

Gregory P. Rodgers
Direct Dial: 212-906-2918
greg.rodgers@lw.com

LATHAM & WATKINS LLP

July 15, 2016

53rd at Third
885 Third Avenue
New York, New York 10022-4834
Tel: +1.212.906.1200 Fax: +1.212.751.4864
www.lw.com

FIRM / AFFILIATE OFFICES

Barcelona	Moscow
Beijing	Munich
Boston	New Jersey
Brussels	New York
Century City	Orange County
Chicago	Paris
Dubai	Riyadh
Düsseldorf	Rome
Frankfurt	San Diego
Hamburg	San Francisco
Hong Kong	Shanghai
Houston	Silicon Valley
London	Singapore
Los Angeles	Tokyo
Madrid	Washington, D.C.
Milan	

VIA EDGAR AND OVERNIGHT DELIVERY

CONFIDENTIAL

Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Kathleen Suellentrop and James Lopez

FOIA Confidential Treatment Request
Under 17 C.F.R §200.83

**Re: Medpace Holdings, Inc.
Form S-1 (File No. 333-212236)**

Ladies and Gentlemen:

Reference is made to the telephonic discussion on June 21, 2016 among representatives of the Staff (the “**Staff**”) of the Division of Corporation Finance of the Securities and Exchange Commission, Medpace Holdings, Inc. (the “**Company**”) and Latham & Watkins regarding the Company’s testing the waters materials provided to the Staff supplementally on June 14, 2016. In response to the Staff’s question regarding slide 8, the Company confirms to the Staff that the information on slide 8 conforms to the information in Figure 7 on page 12 of the Citeline Pharma R&D Annual Review 2016 source (the “**Citeline Source**”), other than the omission of the information for the Biotechnology and Reformulations categories. The Company notes that this information was omitted from slide 8 because the categories Biotechnology and Reformulations are not therapeutic areas, but rather are broader categories that could include drugs under development across different therapeutic areas. *. Therefore, the Company omitted this information from slide 8 since it would not be meaningful to an investor given the Company’s focus on its core therapeutic areas. The Company intends to update its disclosure on slide 8 and has updated its disclosure in the Registration Statement to note that its core therapeutic expertise covers the therapeutic areas where a majority of all drugs are currently in development, rather than over 70%.

The Company respectfully requests that the information contained in this request letter be treated as confidential information and that the Commission provide timely notice to Dr. August J. Troendle, President and Chief Executive Officer, Medpace Holdings, Inc., 5375 Medpace Way, Cincinnati, Ohio 45227, telephone (513) 579-9911, before it permits any disclosure of the underlined and highlighted information contained in this request letter.

Please direct any questions or comments regarding this letter or the Registration Statement to the undersigned at (212) 906-2918. Thank you for your assistance.

[Signature Page Follows]

<p>CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY MEDPACE HOLDINGS, INC.</p>

Very truly yours,

/s/ Gregory P. Rodgers

Gregory P. Rodgers,
of LATHAM & WATKINS LLP

Enclosures

cc:

Dr. August J. Troendle, Medpace Holdings, Inc.
Jesse J. Geiger, Medpace Holdings, Inc.
Stephen P. Ewald, Esq., Medpace Holdings, Inc.
Howard A. Sobel, Esq., Latham & Watkins LLP

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY MEDPACE HOLDINGS, INC.